HAYA, Lilly Launch Up-to-$1B Metabolic Collaboration

Sep 4, 2024 · HAYA, Lilly Launch Up-to-$1B Metabolic Collaboration. Pharma giant plans to apply Swiss biotech’s RNA-guided regulatory genome platform to support preclinical drug discovery …

CouponFollow Extension

$1
OFF

HAYA, Lilly Launch Up-to-$1B Metabolic Collaboration

4 weeks from now

Sep 4, 2024 · HAYA, Lilly Launch Up-to-$1B Metabolic Collaboration. Pharma giant plans to apply Swiss biotech’s RNA-guided regulatory genome platform to support preclinical drug discovery …

genengnews.com

$1
OFF

Lilly, Haya Ink $1B Biobuck Obesity Pact To Search Dark Genome

4 weeks from now

Sep 4, 2024 · The Big Pharma has put together a deal worth up to $1 billion in biobucks to partner with Haya Therapeutics to find multiple regulatory-genome-derived RNA-based drug targets. …

fiercebiotech.com

98%
OFF

HAYA, Lilly Launch Up-to-$1B Metabolic Collaboration

4 weeks from now

Sep 4, 2024 · The noncoding portion that makes up 98% of the human genome is anything but “junk” to HAYA Therapeutics, which said it is partnering with Eli Lilly to identify multiple …

sdbn.org

$1
OFF

Eli Lilly And HAYA Therapeutics Enter Metabolic Condition …

4 weeks from now

Sep 6, 2024 · Eli Lilly and HAYA Therapeutics have entered into a multi-year agreement worth up $1bn to discover regulatory genome targets for obesity and related metabolic conditions. The …

pmlive.com

$1
OFF

HAYA And Lilly Announce $1 Billion Collaboration To Develop RNA ...

4 weeks from now

Sep 4, 2024 · HAYA Therapeutics and Eli Lilly announced a multi-year collaboration focused on developing RNA therapies for obesity and related metabolic conditionsThe collaboration will …

navlindaily.com

$1
OFF

Lilly, Haya Ink Potential $1B Drug Discovery Deal To Target

4 weeks from now

Sep 4, 2024 · Eli Lilly is diving further into the obesity space with a potential billion-dollar deal with Haya Therapeutics. The companies announced a collaboration Wednesday to utilize the Swiss …

biospace.com

$1
OFF

Lilly Lays Down $1B To Be ‘first In Biology’ With Obesity Gene ...

4 weeks from now

Sep 9, 2024 · In addition, Lilly has focused on growing its genetic medicine portfolio with DNA- and RNA-based therapies for metabolic diseases. Even with more competitors developing …

pharmavoice.com

$855
OFF

Lilly Taps Haya For Weight-loss Collaboration

4 weeks from now

Sep 9, 2024 · Eli Lilly and Company—whose market capitalization currently hovers around $855 billion because of the commercial success of its weight-loss drugs Mounjaro and …

acs.org

$1
OFF

Eli Lilly’s Quest For Obesity Drugs Leads To $1B Bet On Dark Genome

4 weeks from now

Eli Lilly (NYSE:LLY) has inked a deal worth up to $1B with HAYA Therapeutics, a biotech focused on a cell information processing unit known as the dark genome, to develop drugs for …

msn.com

$1
OFF

Lilly Taps RNA Biotech For $1 Billion Weight-loss Collaboration

4 weeks from now

Sep 4, 2024 · The Lilly-Haya deal marks the second Big Pharma collaboration in as many weeks to focus on lncRNAs. Bayer recently agreed to pay NextRNA Therapeutics up to $547 million …

acs.org

$1
OFF

Haya, Lilly Target Metabolic Disorders With $1B LncRNA Pact

4 weeks from now

Sep 4, 2024 · The dark matter of long non-coding RNA (lncRNA) is shades brighter, after the signing of two major deals between biotech pioneers and big pharma in the past week. Haya …

bioworld.com

$1
OFF

Eli Lilly Bets Up To $1B In Haya Deal For Obesity (NYSE:LLY)

4 weeks from now

Eli Lilly (NYSE:LLY) has inked a deal worth up to $1B with HAYA Therapeutics, a biotech focused on a cell information processing unit known as the dark genome, to develop drugs for …

seekingalpha.com

$1
OFF

HAYA Therapeutics On LinkedIn: HAYA, Lilly Launch Up-to-$1B …

4 weeks from now

HAYA, Lilly Launch Up-to-$1B Metabolic Collaboration. We are thrilled to announce a multi-year collaboration with Eli Lilly and Company to discover novel regulatory genome targets for …

linkedin.com

FAQs about HAYA, Lilly Launch Up-to-$1B Metabolic Collaboration Coupon?

Does Eli Lilly have a deal with Haya Therapeutics?

Eli Lilly (NYSE: LLY) has inked a deal worth up to $1B with HAYA Therapeutics, a biotech focused on a cell information processing unit known as the dark genome, to develop drugs for metabolic diseases, including obesity. ...

Is Haya a 'junk' to Eli Lilly?

The noncoding portion that makes up 98% of the human genome is anything but “junk” to HAYA Therapeutics, which said it is partnering with Eli Lilly to identify multiple regulatory genome-derived RNA-based drug targets for obesity and related metabolic conditions through a collaboration that could generate up to $1 billion for the Swiss biotech. ...

What is Haya & LLY doing to fight obesity?

Haya develops drugs targeting regulatory RNAs derived from the dark genome. Indiana-based LLY has an expansive obesity pipeline led by its FDA-approved dual GLP-1/GIP receptor agonist, tirzepatide, which is approved for weight loss diabetes and is under investigation for multiple metabolic diseases. ...

What is Haya's lncRNA collaboration?

This collaboration will utilize HAYA’s full-stack regulatory genome platform to identify, characterize and validate multiple novel lncRNA targets for the potential development of new treatments for obesity and related metabolic disorders. ...

Is Haya the next big thing in weight management?

Haya is the latest beneficiary of the Big Pharma’s appetite for the next big thing in weight management. “Haya’s technology offers a new approach to addressing obesity and related metabolic conditions,” Haya CEO Samir Ounzain said in a Sept. 4 release. ...

Will Lilly pay Haya a $1 billion lncRNA investment?

Lilly has agreed to pay HAYA an undisclosed upfront payment, including an equity investment, as well as up to $1 billion in payments tied to achieving preclinical, clinical, and commercial milestones, plus royalties on product sales. Lilly is the second big-name biopharma to invest in an lncRNA collaboration in as many weeks. ...